ReviewFrontiers in immunology2026
From stasis to systematics: deciphering the pathophysiology of secondary lymphedema through omics.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Secondary lymphedema (LE) can ensue after disruption of lymphatic vasculature, which may be caused by infection, surgery, or cancer treatment. Omics technologies can move the field beyond an anatomic description of lymphatic stasis by defining inflammatory, fibrotic, metabolic, lymphatic vascular, and genetic susceptibility programs that shape disease onset and progression. This review summarizes studies that use transcriptomic, proteomic, metabolomic, lipidomic, and emerging genomic or computational approaches in secondary LE. We synthesize how these datasets have identified candidate biomarkers, cell populations, signaling pathways, and therapeutic targets; highlight limitations of current platforms, samples, and bioinformatic pipelines; and propose future multi-omics strategies for diagnosis, risk stratification, and treatment development of secondary LE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.